In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor

被引:51
|
作者
Singh, Pushpendra [1 ]
Bast, Felix [1 ]
机构
[1] Cent Univ Punjab, Ctr Biosci, Sch Basic & Appl Sci, Bathinda 151001, Punjab, India
关键词
Cancer; Epidermal growth factor receptor; Mutation; Natural compound; Maestro 9.3 (Schrodinger 2012); CELL LUNG-CANCER; PROSTATE-CANCER; KINASE INHIBITORS; TYROSINE KINASES; ANDROGEN RECEPTOR; ACCURATE DOCKING; DOWN-REGULATION; T790M MUTATION; EGFR T790M; GEFITINIB;
D O I
10.1007/s00044-014-1090-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The role played by overexpression of tyrosine kinase epidermal growth factor receptor (EGFR), the transmembrane receptor central to numerous cellular processes comprising cell migration, adhesion, apoptosis, and cell proliferation, has been highlighted in various cancers such as prostate, breast, lung, and ovarian cancers as well as in mutations in the EGFR kinase domain. Although many therapeutic approaches have targetted EGFR, the mutations occurring in the EGFR kinase domain including L858 EGFR and T790/L858R had led to the amplification of EGFR signals, consequently leading to increased cell proliferation and cell growth. The strategies involving the inhibition of EGFR L858 and T790M have been accredited with limited achievement in addition to being associated with unwanted adverse effects as a result of crosstalk of wild-type EGFR. All current EGFR tyrosine kinase inhibitors have been identified as ATP competitive inhibitors of wild-type EGFR possessing aniline and quinazoline moiety on the ligands skeleton. Our results obtained by performing molecular docking study on Maestro 9.3 molecular docking suite indicated that CID5280343 possesses better energy conformation against wild-type EGFR as well as two mutated EGFR. Moreover, it was discovered in this study that the natural compounds CID72276, CID5280445, CID441794, and CID72277 and InterBioScreen's library STOCK1N-78657, STOCK1N-78976, and STOCK1N-78847 have better binding conformation against gatekeeper T790M mutated EGFR concluded to be brought about by means of flexible ligands/receptor-based molecular docking protocol. Miraculous features of these compounds are their various pharmacokinetic and pharmacodynamic parameters which were found to be satisfactory as drug-like molecules. This molecular docking study also summarizes docking free energy, protein-ligands interaction profile, and pharmacokinetic and pharmacodynamic parameter of lead molecules which were tremendously helpful in enhancing the activity of these natural compounds against EGFR.
引用
收藏
页码:5074 / 5085
页数:12
相关论文
共 50 条
  • [41] Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma
    Kamigaichi, Atsushi
    Mimae, Takahiro
    Tsubokawa, Norifumi
    Miyata, Yoshihiro
    Adachi, Hiroyuki
    Shimada, Yoshihisa
    Ito, Hiroyuki
    Ikeda, Norihiko
    Okada, Morihito
    ANNALS OF THORACIC SURGERY, 2024, 117 (04): : 743 - 751
  • [42] The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris
    Aydingoz, Ikbal Esen
    Demirci, Gulsen Tukenmez
    Agirbasli, Deniz
    Oz-Arslan, Devrim
    Yenmis, Guven
    JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (01) : 346 - 351
  • [43] EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION STATUS: DOES YOUNGER MEAN MORE FREQUENTLY MUTATED?
    Wojcik, P.
    Krawczyk, P.
    Chorostowska-Wynimko, J.
    Reszka, K.
    Duk, K.
    Muszczynska-Bernhard, B.
    Pankowski, J.
    Wojas-Krawczyk, K.
    Czyzewicz, G.
    Ramlau, R.
    Skoczek, M.
    Grenda, A.
    Orlowski, T.
    Grodzki, T.
    Piwowar, M.
    Roszkowski-Sliz, K.
    Milanowski, J.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2017, 20 (02) : 89 - 90
  • [44] A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South
    Kelly, D.
    Mc Sorley, L.
    O'Shea, E.
    Mc Carthy, E.
    Bowe, S.
    Brady, C.
    Sui, J.
    Dawod, M. A.
    O'Brien, O.
    Graham, D.
    McCarthy, J.
    Burke, L.
    Power, D.
    O'Reilly, S.
    Bambury, R. M.
    Mahony, D. O.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (04) : 855 - 857
  • [45] Eosinophilic Myocarditis Following Osimertinib Treatment for Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma
    Andersson, Charlotte
    McCarter, Kaitlin
    Ruberg, Frederick
    Meier-Ewert, Hans
    Tapan, Umit
    Siddiqi, Omar
    CIRCULATION, 2021, 144
  • [46] Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
    Gini, Beatrice
    Thomas, Nicholas
    Blakely, Collin M.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2883 - 2895
  • [47] IMMUNOHISTOCHEMICAL STUDY OF EPIDERMAL GROWTH-FACTOR AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN GASTRIC-CARCINOMA
    SUGIYAMA, K
    YONEMURA, Y
    MIYAZAKI, I
    CANCER, 1989, 63 (08) : 1557 - 1561
  • [48] IMMUNOHISTOCHEMICAL STUDY OF EPIDERMAL GROWTH-FACTOR AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN BREAST-CARCINOMA
    NOGUCHI, M
    MIZUKAMI, Y
    KINOSHITA, K
    EARASHI, M
    THOMAS, M
    MIYAZAKI, I
    ONCOLOGY REPORTS, 1994, 1 (02) : 381 - 385
  • [49] Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population
    Inagaki, Mieko
    Yoshida, Shigeki
    Kennedy, Stephen
    Takemura, Naoya
    Deguchi, Masashi
    Ohara, Noriyuki
    Maruo, Takeshi
    GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (08) : 474 - 478
  • [50] EPIDERMAL GROWTH FACTOR RECEPTOR(EGFR) DEPHOSPHORYLATION AND GROWTH INHIBITION BY VINORELBINE IN EGFR-MUTATED CELL LINE
    Izumi, Hiroki
    Igishi, Tadashi
    Matsumoto, Shingo
    Ueda, Yasuto
    Takeda, Kenichi
    Touge, Hirokazu
    Makino, Haruhiko
    Kodani, Masahiro
    Chaitanya, S. Nirodi
    Shimizu, Eiji
    ANNALS OF ONCOLOGY, 2014, 25